Study Reveals Treatment Strategy for Triple-Negative Breast Cancer

Article
Conference|American Association for Cancer Research Annual Meeting (AACR)

Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.

Mateusz Opyrchal, MD, PhD, of Roswell Park Cancer Institute in Buffalo, talks about a novel interaction between AURKA and the MAPK pathway in wild-type BRAF breast cancer cells and the cytotoxic effect of AURKA- and MEK1/2-specific inhibitors against estrogen-positive and triple-negative breast cancer cells.

Dr. Opyrchal gave a presentation at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

 

 

Recent Videos
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Related Content
67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

"Policy changes aimed at supporting and more broadly enabling breastfeeding, addressing structural barriers, and promoting a culture shift could reduce overall incidence and racial disparities in TNBC incidence in the [US]," according to the study authors.

Breastfeeding Support May Reduce TNBC Incidence, Mitigate Disparities

Russ Conroy
May 10th 2025
Article

Policy changes supporting breastfeeding may address structural barriers and lower overall incidence and racial disparities surrounding TNBC in the US.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

70 Malignancy Upgrade Rates of Discordant Breast Lesions

70 Malignancy Upgrade Rates of Discordant Breast Lesions

Jacquelyn Dillon;Carolyn Vanek;Jeanne Wu;Grace Van Hyfte;Victoria Collins;Christine Chen;Elisa Port;Jennifer L. Marti
May 9th 2025
Article
71 Beyond the Surface: Suspicious Nipple Lesions

71 Beyond the Surface: Suspicious Nipple Lesions

Margarita Riojas Barrett;Logan Healy;Neil Farnsworth;Elizabeth Bonefas;Alastair Thompson;Stacey Carter
May 8th 2025
Article